Purpose: Patients with malignant pleural mesothelioma, a rapidly progressing malignancy
with a median survival time of 6 to 9 months, have previously responded poorly to …

Purpose This multicenter, phase II clinical study was conducted to evaluate the activity of the
combination of pemetrexed and carboplatin in patients with malignant pleural mesothelioma …

Background:: A phase III trial in patients with malignant pleural mesothelioma demonstrated
a survival advantage for pemetrexed plus cisplatin compared with single-agent cisplatin …

Purpose: This phase II clinical study evaluated the efficacy of pemetrexed for the treatment of
malignant pleural mesothelioma (MPM). Patients and Methods: Patients with a histologically …

PURPOSE: To determine the maximum tolerated dose (MTD) of pemetrexed and carboplatin
given in combination, to derive a recommended dose for phase II studies, and to explore its …

BACKGROUND Malignant pleural mesothelioma (MPM) is increasing rapidly worldwide.
Currently, pemetrexed plus cisplatin chemotherapy showed a survival advantage versus …

Purpose: This report describes the data and analysis leading to the approval of pemetrexed
(LY 231514, MTA, Alimta, Eli Lilly and Co., Indianapolis, IN) by the US Food and Drug …

Background This clinical practice guideline, based on a systematic review, was developed
to determine which chemotherapeutic agents (or combinations of agents) show the highest …

Introduction Previously published results from a randomized phase III study of pemetrexed
plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a …

Background The aim of this study was to evaluate the activity and toxicity of pemetrexed and
carboplatin combination as first-line chemotherapy in malignant pleural mesothelioma …